查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1728202

色素沉著障礙治療市場－全球產業規模、佔有率、趨勢、機會和預測，按適應症、治療和療法、最終用戶、地區和競爭細分，2020-2030 年預測

Pigmentation Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Indication, by Treatment & Therapies, by End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球色素沉著障礙治療市場價值為 67.8 億美元，預計到 2030 年將達到 102.5 億美元，預測期內複合年成長率為 7.13%。色素沉澱障礙包括色素沉澱和色素沉澱過少，會因日曬、遺傳、發炎和荷爾蒙變化等因素影響皮膚顏色。這些情況可能會導致明顯的美容問題，導致許多人尋求治療以獲得更清晰、更均勻的膚色。隨著人們意識的增強和對美學的日益重視，對外用藥物、化學換膚、雷射療法和磨皮等治療的需求持續成長。人口老化、皮膚病學技術創新以及先進配方和設備的引進進一步推動了市場擴張。此外，以護膚為重點的消費者教育和產品開發的激增（特別是含有對苯二酚和煙醯胺等活性成分的乳霜）對市場的成長軌跡做出了重大貢獻。

市場概覽
預測期 2026-2030
2024年市場規模 67.8億美元
2030年市場規模 102.5億美元
2025-2030 年複合年成長率 7.13%
成長最快的領域 皮膚科診所
最大的市場 北美洲

關鍵市場促進因素

技術進步

主要市場挑戰

治療費用

主要市場趨勢

個人化醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球色素沉著障礙治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依適應症（色素沉澱、色素沉澱過少）
    • 依治療及療法分類（化學換膚、磨皮、雷射換膚、黃褐斑）
    • 按最終使用者（皮膚科診所、醫院）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：亞太地區色素沉著障礙治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第7章：歐洲色素沉著障礙治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第8章：北美色素沉著障礙治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：南美色素沉著障礙治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲色素沉著障礙治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球色素沉著障礙治療市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • Zerigo Health.
  • Bausch Health Companies Inc.
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • CLINUVEL PHARMACEUTICALS LTD
  • Strides Pharma Science Limited
  • Astellas Pharma Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 16971

The Global Pigmentation Disorders Treatment Market was valued at USD 6.78 Billion in 2024 and is projected to reach USD 10.25 Billion by 2030, growing at a CAGR of 7.13% during the forecast period. Pigmentation disorders, encompassing hyperpigmentation and hypopigmentation, affect skin coloration due to factors such as sun exposure, genetics, inflammation, and hormonal changes. These conditions can result in noticeable cosmetic concerns, leading many individuals to seek treatment for clearer, more even-toned skin. With rising awareness and the increasing emphasis on aesthetics, demand for treatments like topical agents, chemical peels, laser therapies, and dermabrasion continues to grow. Aging populations, technological innovation in dermatology, and the introduction of advanced formulations and devices have further propelled market expansion. Additionally, a surge in skincare-focused consumer education and product development-particularly creams containing active ingredients such as hydroquinone and niacinamide-has significantly contributed to the market's growth trajectory.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.78 Billion
Market Size 2030USD 10.25 Billion
CAGR 2025-20307.13%
Fastest Growing SegmentDermatology Clinics
Largest MarketNorth America

Key Market Drivers

Technological Advancements

Rapid advancements in technology have greatly enhanced the effectiveness and precision of pigmentation disorder treatments. Innovations in laser-based therapies, including Q-switched, fractional, and picosecond lasers, have enabled targeted treatment of pigmented lesions with minimal risk of scarring. The adoption of Intense Pulsed Light (IPL) systems has broadened treatment accessibility for conditions such as age spots and sun-induced pigmentation. In addition, fractional radiofrequency (RF) devices that integrate microneedling with RF energy offer effective non-invasive treatment with minimal downtime. The refinement of topical formulations through nanotechnology and enhanced transdermal delivery systems has increased the potency and bioavailability of active ingredients. Cryotherapy tools with improved temperature control, along with the emergence of picosecond lasers capable of ultra-short pulse durations, have expanded therapeutic options, especially for resistant pigmentation conditions. These technological strides have collectively improved clinical outcomes and patient satisfaction across diverse skin types and indications.

Key Market Challenges

Cost of Treatment

The high cost of pigmentation treatment poses a significant challenge for broader market accessibility. Procedures such as laser therapy and combination treatment plans can be expensive, especially when multiple sessions are required for optimal results. Out-of-pocket expenses can be substantial, particularly in regions where pigmentation therapy is classified as elective and not covered by insurance. Beyond procedural fees, patients also bear the costs of consultation, follow-ups, prescription creams, and maintenance therapies. Premium skincare products designed for pigmentation disorders can be financially burdensome, and specialized treatments often involve travel to advanced dermatology centers, further escalating costs. The long-term nature of treatment, requiring consistent care and follow-up, adds to the financial strain, thereby limiting treatment adoption among cost-sensitive populations.

Key Market Trends

Personalized Medicine

The shift toward personalized medicine is transforming the treatment of pigmentation disorders. Tailored therapeutic strategies are now being developed based on individual patient factors such as genetic profile, skin type, lifestyle, and prior treatment responses. Genetic insights have enabled identification of mutations and variations linked to pigmentation irregularities, helping clinicians develop targeted therapies. Pharmacogenomic testing further refines this approach by determining the most effective drug or topical agent based on an individual's genetic makeup. Skin type-specific therapies and the integration of multimodal treatments-such as combining chemical peels with laser resurfacing-are gaining traction. Moreover, advancements in laser technology now permit customization of wavelength and energy settings based on patient-specific needs. Empowering patients with information and involving them in treatment decisions is also a key feature of this trend, contributing to improved adherence and satisfaction.

Key Market Players

  • Zerigo Health
  • Bausch Health Companies Inc.
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
  • CLINUVEL PHARMACEUTICALS LTD
  • Strides Pharma Science Limited
  • Astellas Pharma Inc.

Report Scope:

In this report, the Global Pigmentation Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pigmentation Disorders Treatment Market, By Indication:

  • Hyperpigmentation
  • Hypopigmentation

Pigmentation Disorders Treatment Market, By Treatment & Therapies:

  • Chemical Peels
  • Dermabrasion
  • Laser Resurfacing
  • Melasma

Pigmentation Disorders Treatment Market, By End User:

  • Dermatology Clinics
  • Hospitals

Pigmentation Disorders Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pigmentation Disorders Treatment Market.

Available Customizations:

Global Pigmentation Disorders Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pigmentation Disorders Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Hyperpigmentation, Hypopigmentation)
    • 5.2.2. By Treatment & Therapies (Chemical Peels, Dermabrasion, Laser Resurfacing, Melasma)
    • 5.2.3. By End User (Dermatology Clinics, Hospitals),
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Pigmentation Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Treatment & Therapies
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Pigmentation Disorders Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Treatment & Therapies
        • 6.3.1.2.3. By End User
    • 6.3.2. India Pigmentation Disorders Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Treatment & Therapies
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Pigmentation Disorders Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Treatment & Therapies
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Pigmentation Disorders Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Treatment & Therapies
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Pigmentation Disorders Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Treatment & Therapies
        • 6.3.5.2.3. By End User

7. Europe Pigmentation Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Treatment & Therapies
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pigmentation Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Treatment & Therapies
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Pigmentation Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Treatment & Therapies
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Pigmentation Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Treatment & Therapies
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pigmentation Disorders Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Treatment & Therapies
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Pigmentation Disorders Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Treatment & Therapies
        • 7.3.5.2.3. By End User

8. North America Pigmentation Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Treatment & Therapies
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Pigmentation Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Treatment & Therapies
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Pigmentation Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Treatment & Therapies
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Pigmentation Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Treatment & Therapies
        • 8.3.3.2.3. By End User

9. South America Pigmentation Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Treatment & Therapies
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pigmentation Disorders Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Treatment & Therapies
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Pigmentation Disorders Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Treatment & Therapies
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Pigmentation Disorders Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Treatment & Therapies
        • 9.3.3.2.3. By End User

10. Middle East and Africa Pigmentation Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Treatment & Therapies
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pigmentation Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Treatment & Therapies
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Pigmentation Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Treatment & Therapies
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Pigmentation Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Treatment & Therapies
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Pigmentation Disorders Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Zerigo Health.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Bausch Health Companies Inc.
  • 16.3. Glenmark Pharmaceuticals Limited
  • 16.4. Novartis AG
  • 16.5. Pfizer Inc.
  • 16.6. Teva Pharmaceutical Industries Ltd.
  • 16.7. Bayer AG
  • 16.8. CLINUVEL PHARMACEUTICALS LTD
  • 16.9. Strides Pharma Science Limited
  • 16.10.Astellas Pharma Inc.

17. Strategic Recommendations

18. About Us & Disclaimer